

REVIEWS

Open Access



Physiological adaptations during weaning from veno-venous extracorporeal membrane oxygenation

Patrick Duncan Collins^{1*} , Lorenzo Giosa^{1,2}, Valentina Camarda¹ and Luigi Camporota^{1,2}

*Correspondence:
patrick.collins@gstt.nhs.uk

¹ Department of Critical Care Medicine, Guy's and St. Thomas' National Health Service Foundation Trust, London, UK

² Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, King's College London, London, UK

Abstract

Veno-venous extracorporeal membrane oxygenation (V–V ECMO) has an established evidence base in acute respiratory distress syndrome (ARDS) and has seen exponential growth in its use over the past decades. However, there is a paucity of evidence regarding the approach to weaning, with variation of practice and outcomes between centres. Preconditions for weaning, management of patients' sedation and mechanical ventilation during this phase, criteria defining success or failure, and the optimal duration of a trial prior to decannulation are all debated subjects. Moreover, there is no prospective evidence demonstrating the superiority of weaning the sweep gas flow (SGF), the extracorporeal blood flow (ECBF) or the fraction of oxygen of the SGF (FdO₂), thereby a broad inter-centre variability exists in this regard. Accordingly, the aim of this review is to discuss the required physiological basis to interpret different weaning approaches: first, we will outline the physiological changes in blood gases which should be expected from manipulations of ECBF, SGF and FdO₂. Subsequently, we will describe the resulting adaptation of patients' control of breathing, with special reference to the effects of weaning on respiratory effort. Finally, we will discuss pertinent elements of the monitoring and mechanical ventilation of passive and spontaneously breathing patients during a weaning trial. Indeed, to avoid lung injury, invasive monitoring is often required in patients making spontaneous effort, as pressures measured at the airway may not reflect the degree of lung strain. In the absence of evidence, our approach to weaning is driven largely by an understanding of physiology.

Take home message

Successful weaning from veno-venous ECMO requires understanding and consideration of the complex physiological interactions between the native and the extracorporeal lung. We describe our understanding of the physiological adaptations of the patient as extracorporeal support is weaned and outline the implications for clinical practice.

Keywords: Extracorporeal membrane oxygenation (ECMO), Weaning, Acute respiratory distress syndrome (ARDS), Respiratory drive, Patient self-inflicted lung injury (P-SILI)

Introduction

Veno-venous extracorporeal membrane oxygenation (V–V ECMO) is a technique that can support gas exchange and enable a reduction in the mechanical power applied to the injured lung in patients with acute severe and refractory, but potentially reversible, respiratory failure.

The increasing emphasis on reducing ergotrauma, the technological improvements in the extracorporeal devices, and the viral pandemics (i.e. H₁N₁ influenza and SARS-CoV 2) have resulted in an exponential growth in ECMO utilization over the last decade [1]. The possible applications of V–V ECMO are wide, including severe Acute Respiratory Distress Syndrome (ARDS), near fatal asthma, severe air leak syndromes, interstitial lung disease or as a bridge to lung transplantation [2–6].

In contrast to the abundance of data on indications, complications and prognostic factors for ECMO survival [1–3], consensus guidelines on weaning [6] are based on limited direct evidence on the criteria to initiate a weaning trial, how to monitor patients undergoing weaning and how to adjust mechanical ventilation to optimally support patients during this phase.

In Table 1 [3, 6, 8–20], we summarize the different approaches to weaning of V–V ECMO reported in the literature. Most centres wean the sweep gas flow (SGF) to zero but variable practice regarding manipulation of extracorporeal blood flow (ECBF) or the fraction of oxygen of the SGF (FdO₂) is apparent between centres. Furthermore, the monitoring criteria and duration of a weaning trial are extremely variable, with few centres reporting objective assessment of respiratory drive and effort.

This variation in practice may contribute to inter-centre heterogeneity in V–V ECMO outcome [1]. Identifying strategies which can accelerate the safe liberation of patients from ECMO are essential to reduce length of stay and risk of complications, as well as ensuring equity of access at times of strain on healthcare resources [7].

A sound understanding of the physiological interactions between the extracorporeal circuit, the patient and the ventilator is required to guide physicians throughout the process of weaning. Accordingly, this review aims to describe a possible physiological approach to weaning from V–V ECMO.

Physiology of weaning from V–V ECMO

The extracorporeal circuit

V'O_{2ML}, V'CO_{2ML} and the effects of weaning

The extracorporeal circuit is depicted in Fig. 1. Table 2 summarizes the effects of weaning different ECMO parameters on V'O_{2ML} and V'CO_{2ML}. There are three main settings which can be manipulated during the weaning or trial off V–V ECMO [21]:

Effects of reducing ECBF

The ECBF rate has differing effects on the oxygen delivery (V'O_{2ML}) and CO₂ clearance of the membrane lung (V'CO_{2ML}). With a well-functioning circuit, nearly all haemoglobin passing through the membrane lung will become 100% saturated even at very low SGF rates. Consequently, if the FdO₂ is unchanged, the ECBF is the main titratable variable which can affect the V'O_{2ML}. However, the nature of the

Table 1 Varied approaches to weaning in the literature

Source	Preconditions for weaning	Preferred ventilation	Targeted parameters during weaning			Measured effort/drive	Monitoring criteria for successful trial	
			ECBF (L/min)	FdO ₂	SGF (L/min)			Duration (h)
Sen et al. 2016 [8]	PEEP 5–10, peak pressure 20–25, TV 6 ml/kg, RR ~ 15, PaO ₂ 50–80, radiological improvement	Controlled or spontaneous	2	0.21	0	Unspecified	–	Clinician Discretion
Reeb et al. 2017 [9]	Sats > 88% (PaO ₂ > 60), FiO ₂ ≤ 0.6, PEEP ≤ 15, RR ≤ 35	Not specified	Unspecified	1.0	0	4	–	Stable ABG
Combes et al. 2018 [3]	Clinical + radiological improvement	Controlled	Unspecified	1.0	0	≥ 1	–	PaO ₂ > 70 mmHg on FiO ₂ < 0.6 plateau pressure < 30. No acute cor pulmonale
Broman et al. 2018* [10]	FiO ₂ 0.35–0.55, minimal VCO _{2ML} with 5% CO ₂ added to SGF < 2L/min	Controlled or spontaneous	Unspecified	1.0	0	≥ 2–12	–	Clinician discretion
Broman et al. 2018† [10]	FiO ₂ < 0.45, PEEP < 10, peak pressure < 27	Not specified	1.5	1.0	0	0.5–1	–	Stable ABG and absence of dyspnoea
Broman et al. 2018† [10]	Clinical + radiological improvement	Spontaneous	2.5–3	1.0	0	Unspecified	–	Absence of dyspnoea
Grant et al. 2018 [11]	Sats > 90%, FiO ₂ ≤ 0.5, PEEP ≤ 10, plateau pressure ≤ 25, TV ≤ 6–8ml/kg	Controlled	3–4	0.21	≤ 1L	Unspecified	–	Stable ABG, maintain preconditions
Seiler et al. 2018 [12]	Clinician discretion	Controlled	2	1.0	0	1	–	Stable ABG
Chaves et al. 2019 [13]	FiO ₂ ≤ 0.6, PEEP ≤ 15, peak pressure ≤ 30, TV ≤ 6ml/kg, RR ≤ 35 and radiological improvement	Spontaneous	Unspecified	1.0	0	6	–	Clinical stability, normal pH and PaO ₂
Vasques et al. 2019 [14]	Sats > 88% on FiO ₂ 0.6, PaO ₂ > 225 on Cilley test, VCO _{2NL} > 50% of total, TV ≤ 6–8 ml/kg,	Spontaneous	Unspecified	0.21	0	Unspecified	Yes	P.OI > – 10, RR ≤ 35, ratio of VCO _{2NL} to minute ventilation > 80% of baseline, absence of distress
Li et al. 2020 [15]	Clinical + radiological improvement	Controlled	2.5	1.0	0	24–48	–	RR ≤ 20, P:F ratio > 150, Murray Index 2–3, PaCO ₂ ≤ 50, temperature < 38c

Table 1 (continued)

Source	Preconditions for weaning	Preferred ventilation	Targeted parameters during weaning			Measured effort/drive	Monitoring criteria for successful trial	
			ECBF (L/min)	FdO ₂	SGF (L/min)			Duration (h)
Gannon et al. 2021 [16]	SGF ≤ 3 , Sats $\geq 88\%$ (PaO ₂ ≥ 60) with FIO ₂ ≤ 0.6 , PEEP ≤ 15 , RR ≤ 35 , HR < 120 , systolic BP ≥ 180 or < 90 , pH ≥ 7.35	Controlled or spontaneous	< 3	0.5	0	0.5	–	Maintain non-ECMO preconditions, $\leq 20\%$ change in HR
Tonna et al. (ELSO guideline), 202 [6]	PaO ₂ ≥ 70 FIO ₂ ≤ 0.6 , PEEP ≤ 10 , plateau ≤ 28 , TV ≤ 6 ml/kg, RR ≤ 28 , improved CXR	Controlled or spontaneous	1–1.5**	0.21	0	$\geq 2-3$	–	Normocapnia, PaO ₂ > 70 , no respiratory distress
Teijeiro et al. 2021 [17]	No air leak, No NIMB > 24 h, FIO ₂ ≤ 0.6 Sats $> 88\%$ PaO ₂ > 60 peak pressure ≤ 20 , TV ≤ 9 ml/kg, haemodynamically stable, SGF < 5 , ECBF < 5 ,	Spontaneous	< 5	1.0	0	2–24	–	Respiratory distress, TV > 9 ml/kg, Sats $< 88\%$ (or requiring FIO ₂ > 0.6 , PEEP ≥ 20) pH < 7.25 , haemodynamic instability, agitation or drowsiness
Belliato et al. 2021 [18]	Clinical and radiological improvement, PEEP $\leq 10-15$, haemodynamic stability	Controlled or spontaneous	Unspecified	1.0	0	6–12	–	Clinician discretion
Al-Fares et al. 2021 [19]	Clinician discretion	Controlled or spontaneous	> 3	1.0	0	Unspecified	Yes	Clinician discretion
Lazarri et al. 2022 [20]	Δ Pes ≤ 15 , RR ≤ 30 , pH > 7.25 , PaCO ₂ ≤ 60 , PaO ₂ > 70 with FIO ₂ ≤ 0.6	Controlled or spontaneous	Unspecified	1.0	0	Unspecified	Yes	Maintain preconditions

ECBF: extracorporeal blood flow, FdO₂: fraction of oxygen of the Sweep Gas Flow (SGF), PEEP: positive end expiratory pressure, TV: tidal volume (per kilogram of predicted body weight), RR: respiratory rate, ABG: arterial blood gas, PaO₂: partial pressure of arterial oxygen, PaCO₂: the partial pressure of arterial carbon dioxide, VCO_{2MI}: carbon dioxide cleared by the membrane lung, VCO_{2MI}: carbon dioxide cleared by the native lung, Δ Pes: the change in oesophageal pressure, P:F ratio: ratio of PaO₂ to FIO₂. All airway pressures measured in centimetres of water. All non-airway pressures (including partial pressures) measured in millimetres of mercury. Broman et al. reported an approach from the Karolinska institute*. Regensburg Hospital† and San Raffaele Hospital‡. **A reduction in ECBF is considered optional within the guidelines




Fig. 1 The anatomy and physiology of the extracorporeal circuit, depicted in a femoral–jugular configuration. Blood is drained from the central venous system (C_v) via a cannula and centrifugal pump which generates extracorporeal blood flow (ECBF). Pre-oxygenator blood is a mixture of central venous (C_v) and recirculating (Q_R) blood. It is pumped across hollow fibres within the membrane oxygenator across which there is sweep gas flow (SGF). Post-oxygenator blood passes through the return lumen where it becomes mixed with the C_v blood in the right ventricle and pulmonary arteries to form the mixed venous blood (C_{vmixed}) before being distributed through the native pulmonary circulation. Mixed central venous bloods oxygen content ($C_{vmixed}O_2$) will be determined by: the central venous oxygen content (C_{vO_2}), the post-oxygenator blood's oxygen content ($C_{post-oxy}O_2$), the extracorporeal blood flow (ECBF), recirculation flow (Q_R) and overall cardiac output (Qt) according to the formula: $C_{vmixed}O_2 \cdot Qt = [C_{vO_2} \cdot (Qt - ECBF + Q_R)] + [C_{post-oxy}O_2 \cdot (ECBF - Q_R)]$. Although the ECBF contributes to the calculation of the overall CO_2 clearance of the membrane lung [$V'CO_{2ML} = (C_{post-oxy}CO_2 - C_{pre-oxy}CO_2) \cdot ECBF \cdot 25$], during the usual V–V ECMO ECBF levels (> 2.5 L) the primary determinant of $V'CO_{2ML}$ is the SGF rate which generates the gradient for CO_2 diffusion and resulting difference in pre- and post-oxygenator CO_2 content

relationship between ECBF and the $V'O_{2ML}$ is affected by the amount of recirculated blood flow (Q_R):

1. Recirculation occurs when arterialized blood returned to the venous system after passing through the membrane lung is aspirated straight back into the circuit (see Fig. 1), lowering the gradient between the pre- and post-membrane blood oxygen content and therefore the $V'O_{2ML}$. *Effective* ECBF, equal to total ECBF minus Q_R , is linearly related to $V'O_{2ML}$ [21] but Q_R cannot be easily quantified at the bedside.

Table 2 Titratable ECMO parameters during weaning and their effects

Parameter which can be weaned	Relationship with $V'O_{2ML}$	Relationship with $V'CO_{2ML}$	Downsides of weaning in isolation
ECBF	Linear relationship if Q_R is minimal	Linear relationship between 0 and 0.5 L/min Logarithmic relationship between 0.5 and 1 L/min Minimal change > 1 L/min Influenced by membrane lung surface and SGF	Low ECBF flows may increase circuit thrombosis Changes in ECBF will also affect Q_R
SGF	Minimal change until almost zero	Decrease $V'CO_{2ML}$	When SGF is turned to zero $V'O_{2ML}$ ceases suddenly but hypoxic pulmonary vasoconstriction takes minutes to react
FdO_2	Decrease $V'O_{2ML}$	No effect	Weaning may alter the respiratory quotient and reduce alveolar oxygen

ECBF: extracorporeal blood flow

SGF: sweep gas flow

FdO_2 : fraction of oxygen of the SGF

Q_R : blood flow directly back into the ECMO circuit which has already passed through the membrane lung

- The proportion of Q_R may be higher at higher ECBF. If a given decrease in ECBF during weaning disproportionately reduces Q_R then the change in $V'O_{2ML}$ may not be as anticipated. For example, if the Q_R reduces from 1 L to 250 mL when the ECBF is weaned by 25% from 4 to 3 L/min, then the effective ECBF has only changed from 3 L to 2.75 L. Conversely, when Q_R is minimal decreasing the total ECBF will decrease the $V'O_{2ML}$ linearly [21].

The effect of weaning the ECBF upon the systemic oxygenation will depend on the cardiac output and venous admixture: as the proportion of the total cardiac output captured into the ECBF falls, the mixed venous oxygen content will decrease, and the final effect upon systemic oxygenation will be determined by native lung function.

In contrast to $V'O_{2ML}$, the relationship between ECBF and $V'CO_{2ML}$ is not linear, but follows a natural logarithmic curve with $ECBF > 0.5$ mL/min, which plateaus at > 1.0 L/min [22, 23]. The impact of the ECBF on $V'CO_{2ML}$ is also affected by the ratio of SGF:ECBF and the surface area of the membrane lung [22]. Accordingly, step-wise decreases in ECBF have minimal independent effect on the $V'CO_{2ML}$ until reaching very low levels- which are generally avoided to prevent circuit thrombosis.

Effects of reducing SGF rate without altering the FdO_2

Nearly complete saturation of haemoglobin can be achieved even with very low SGF rates (< 0.5 L/min) particularly when FdO_2 is maintained at 1.0 [21]. For this reason, step decreases in SGF do not affect $V'O_{2ML}$ until SGF is almost off. Moreover, even the small amount of SGF can affect ECMO dependency for another reason: V-V ECMO causes a mixed venous 'hyperoxia', blunting or abolishing the physiological hypoxic pulmonary vasoconstriction [24]. This results in an increased native lung venous admixture, with lower than expected ventilation to perfusion (V_a/Q) ratio [24–26]. Accordingly, when

Table 3 Evaluation of CO₂ clearance of native lung during weaning from V–V ECMO

Parameter	Formula	Downsides/specifics
Ventilatory ratio [28]	$(VE \cdot PaCO_2) / (PBW \cdot 100 \cdot 37.5)$	Assumes constant $V'CO_{2NL}$
Enghoff index	$(PaCO_2 - PECO_2) / PaCO_2$	Evaluates both shunt and dead space
Ratio of end tidal to partial pressure of carbon dioxide	$EtCO_2 / PaCO_2$	Evaluates both shunt and dead space [20]
Bohr alveolar dead space	$(PACO_2 - PECO_2) / PACO_2$	Evaluates pure alveolar dead space but requires analysis of volumetric capnography curve [24]
Ventilatory efficiency	$VE / V'CO_{2NL}$	No available data during ECMO
Ventilatory efficiency	$\Delta P_{esc} / V'CO_{2NL}$	Influenced by lung elastance

PBW: predicted body weight

VE: minute ventilation

PECO₂: mean expired CO₂ partial pressure

PACO₂: alveolar CO₂ partial pressure

the SGF is turned to zero at the last step of a weaning trial, patients are abruptly totally dependent on the native lungs capacity to transfer oxygen ($V'O_{2NL}$), but the biphasic response of the pulmonary vasculature to hypoxia requires minutes to hours to occur [27]. Delayed hypoxic vasoconstriction increases the effective venous admixture, worsening V/Q matching and potentially leading to hypoxaemia which might be avoided with a slower transition.

In contrast to oxygenation, step-wise decreases in SGF are associated with a progressive reduction in $V'CO_{2ML}$ [22]. SGF drives bulk transfer of CO₂ out of the artificial membrane and increases the gradient for CO₂ in the venous blood to diffuse across the membrane. Accordingly, step decreases in SGF, result in a higher CO₂ in the pulmonary vasculature and greater load to the native lung ($V'CO_{2NL}$), whose exchange capacity will affect PaCO₂. Several indices have been proposed for a bedside evaluation of the CO₂ clearance capacity of the natural lung, as summarized in Table 3 [19, 20, 28, 29]. Interestingly, the partial pressure of end tidal to arterial PCO₂ ratio ($P_{ET}:PaCO_2$), an index of global gas-exchange efficiency [30], was the best predictor of weaning outcome in a recent study [together with a measure of ventilatory efficiency (ratio of respiratory effort to $V'CO_{2NL}$)] [20].

When SGF is set to zero, V–V ECMO makes no contribution to gas exchange and, after the restoration of hypoxic pulmonary vasoconstriction, a true assessment of native lung function can occur. A special case in which a sudden reduction in arterial oxygenation is unrelated to a lung function and severe hypoxaemia occurs when there is an intracardiac shunt: in this case, the flow from the return cannula can force blood through the shunt, bypassing the native lung and potentially leading to profound desaturation when SGF falls to zero. This will become evident if ECBF is not concomitantly reduced to < 1 L/min when no compensatory oxygen is added from the extracorporeal circuit [31].

Effects of reducing the FdO₂ prior to reducing the SGF

Gradually reducing the FdO₂ leads to a sequential decrease in $V'O_{2ML}$, while $V'CO_{2ML}$ remains unaltered. The progressive decrease in FdO₂ has the advantage of allowing time to restore hypoxic pulmonary vasoconstriction [21]. This will prevent rapid desaturations and provides a more accurate assessment of the oxygen exchange capacity of the

native lung. The effect on systemic oxygenation of a reduction in $V'O_{2ML}$ through step decreases in FdO_2 will largely depend on the ratio of ECBF to cardiac output and on the venous admixture of the native lung.

However, reductions in FdO_2 may have counter-intuitive effects on the alveolar oxygen partial pressure. If FdO_2 is weaned in isolation (i.e. SGF is maintained constant), the contribution of $V'O_{2ML}$ to total $V'O_2$ falls, whilst the proportion of the total metabolically produced CO_2 cleared by the natural lung remains largely unchanged, or even decreased if metabolic CO_2 production increases with the hypoxic drive, and the native lung is unable to increase CO_2 . In this case, the CO_2 removed extracorporeally proportionally increases. This means that the respiratory quotient of the natural lung ($RQ_{NL} = V'CO_{2NL}; V'O_{2NL}$) will be reduced [32]. The implications of this can be seen from the alveolar gas equation:

$$PAO_2 = PiO_2 - \frac{PACO_2}{RQ_{NL}},$$

where PAO_2 and $PACO_2$ are the alveolar partial pressures of oxygen and carbon dioxide, respectively, and PiO_2 is the pressure of inspired oxygen.

The greater the reduction in RQ_{NL} from the $V'CO_{2ML}$, the lower the PAO_2 . In other words, if $PaCO_2$ is static, the $V'CO_{2ML}$ entails a relative alveolar hypoventilation. This leads to uptake of O_2 by the lungs which is not compensated for by bulk gas transfer, resulting in a lower PAO_2 . However, the clinical significance of this effect during weaning from V–V ECMO should be put into context:

1. The extended alveolar equation has a supplementary term (in bold here below) which, accounting for changes in alveolar gas volume during breathing, blunts the deleterious effect of low RQ on PAO_2 , especially if the FiO_2 from the native lung is high [33, 34]:

$$PAO_2 = PiO_2 - \frac{PACO_2}{RQ_{NL}} + FiO_2 \bullet PACO_2 \bullet \frac{1 - RQ_{NL}}{RQ_{NL}}.$$

2. The reduction in PAO_2 at low RQ_{NL} is most clinically relevant during extracorporeal CO_2 removal (ECCO₂R) [32], where ECBF is < 1 L/min. However, this will be less evident during weaning of V–V ECMO where the ECBF is much higher: indeed, even at FdO_2 0.21, there may still be a substantial $V'O_{2ML}$ [21].

The patient

The patient's response to a weaning trial is dictated by the physiology of breathing control and, particularly, by the effects of variations in gas-exchange on the output of the respiratory centres.

Physiology of breathing control

A simple, yet effective model describing the control of breathing has been proposed by Georgopoulos et al. [35] and subsequently adopted by others [36]. As depicted in Fig. 2 [35–38], this model describes the interdependence between the arterial partial pressure




Fig. 2 Georgopolous model of breathing control during weaning. **A** Reflects health, where the brain and ventilation curve are synonymous, thereby eupneic and actual PaCO_2 coincide. Possible contributors to the position of the brain curve, ventilation curve and metabolic hyperbola, and the varying slope of the latter (larger ΔVE required to achieve a given ΔPaCO_2 when ventilation is higher) are also shown. **B** Represents a possible SGF weaning trial off: as the CO_2 cleared by the membrane lung ($\text{V}'\text{CO}_{2\text{ML}}$) is reduced the metabolic hyperbola shifts upwards and to the right, while the brain and ventilation curve shift in parallel to the left to maintain the eupneic PaCO_2 . **C** Represents a possible FdO_2 or ECBF weaning trial off: as the oxygen provided by the membrane lung ($\text{V}'\text{O}_{2\text{ML}}$) is reduced during weaning any hypoxaemia would shift the position and slope of the brain curve a new eupneic PaCO_2 . This new equilibration point will drive non-metabolic CO_2 from body stores into the bloodstream possibly shifting the metabolic hyperbola upward and to the right. **D** Depicts possible weaning-induced changes in the relative position of the brain and ventilation curves (maintained synonymous for simplicity in all other Panels): note that any deviation between the two curves induces a difference between the actual and eupneic CO_2 . MV: mechanical ventilation, PaCO_2 : the partial pressure of arterial carbon dioxide, $\text{V}'\text{CO}_{2\text{NL}}$: the total CO_2 to be cleared by the natural lung, Vd/Vt the dead space fraction of the tidal volume, $\text{V}'\text{CO}_{2\text{ML}}$: the CO_2 cleared by the membrane lung

of CO_2 (PaCO_2) and the minute ventilation (VE) by plotting them in the same graph according to three different curves: (1) the *metabolic hyperbola*, describing the relationship between PaCO_2 and VE at a given $\text{V}'\text{CO}_{2\text{NL}}$ and dead space (Vd/Vt); (2) the CO_2 sensitivity curve (also called the *brain curve*), describing the change in VE that the respiratory centres desire when PaCO_2 deviates from its set-point; (3) the *ventilation curve*, depicting the corresponding change in VE that the respiratory system can actually achieve for a given PaCO_2 . In health, the brain and ventilation curves are synonymous.

The intersection between the brain curve and the metabolic hyperbola gives the 'eupneic' PaCO_2 , i.e. the PaCO_2 set-point of the respiratory centres. Conversely, the intersection between the ventilation curve and the metabolic hyperbola gives the actual PaCO_2 of the patient. Panel A in Fig. 2 describes physiological and pathological determinants of the slopes and positions of these three curves [35, 36].

Effects of weaning on respiratory centres output

According to the Georgopoulos model, weaning may affect the respiratory centres' output through the following mechanisms.

Step decreases in SGF may change the position of the metabolic hyperbola

Normally, around 6–7 L/min of VE is sufficient to maintain a PaCO₂ at 40 mmHg at physiologic VCO_{2NL}. During V–V ECMO, VCO_{2NL} decreases and the metabolic hyperbola shifts downward and to the left (i.e. lower VE is required to maintain the same PaCO₂). Conversely, during weaning, step decreases in SGF rate reduce V'CO_{2ML} and the total metabolic V'CO₂ increases at higher work of breathing. For both reasons, V'CO_{2NL} is expected to increase, shifting the metabolic hyperbola upward and to the right (see Panel B in Fig. 2).

Step decreases in FdO₂ or ECBF may change the set-point of the brain curve

Normally, the brain is set to maintain a PaCO₂ around 40 mmHg. However, chemical (PaO₂ and pH), reflex (lung and chest wall receptors) and cortical (wakefulness, sedation, agitation) inputs can change the set-point to lower or higher values. In ARDS, stimulation of lung mechanoreceptors and inflammation contribute to a low PaCO₂ set-point even in normoxia. For this reason, even with maximal V'CO_{2ML} it is uncommon to induce apnoea during V–V ECMO for ARDS [39]. During weaning, step decreases in V'O_{2ML} may induce hypoxemia, thereby lowering the PaCO₂ set-point. This will result in the brain curve shifting to the left and increasing its slope (see Panel C in Fig. 2).

Changes in breathing pattern may affect the ventilation curve

In health, ventilation satisfies the activity of the respiratory centres, thereby the ventilation and brain curve overlap and the actual PaCO₂ matches the eupnoeic PaCO₂. In ARDS, the descending pathway from the brain to the lung is altered. Dissociation between the two curves results in dyspnoea and further increasing the already high respiratory centres output. During weaning, elicited natural lung ventilation might decrease lung elastance (intra-tidal recruitment) [40] or resistances (inversely correlated with tidal volume [41]), thereby partially re-establishing the matching between the brain and the ventilation curve. On the other hand, neuromechanical uncoupling may worsen if PEEP is increased without corresponding recruitment [42] or if muscular fatigue is associated with inadequate support. Accordingly, the dissociation between the brain and the ventilation curve may increase (see Panel D in Fig. 2).

There are other important interactions which are particularly relevant in the spontaneously breathing patient:

1. With increasing VCO_{2NL}, shifting the metabolic hyperbola upward and to the right would result in increased PaCO₂ if the brain curve did not concomitantly change position (see Fig. 2 Panel B). However, it has been experimentally shown that PaCO₂ remains constant at decreasing SGF, unless extreme effort is reached [20]. A similar behaviour of the respiratory centres occurs in exercise, where increasing VCO_{2NL}

is associated with a parallel leftward shift of the brain curve (at constant slope) to maintain constant PaCO₂ (isocapnic hyperpnea) [37]. The underlying mechanism explaining this phenomenon remains debated [43].

2. When the brain curve shifts to lower PaCO₂ set points, the entire pool of CO₂ body stores must equilibrate with the new PaCO₂ (see Fig. 2 panel C). This requires displacement of a vast amount of non-metabolic CO₂ from peripheral tissues into the bloodstream increasing V'CO_{2NL} [44] and further shifting the metabolic hyperbola upward and to the right. The higher the pool of total body CO₂ stores (for example due to prior permissive hypercapnia), the greater the amount of CO₂ displaced to reach equilibrium and therefore the greater V'CO_{2NL} which may be required to maintain the new set-point.
3. The slope of the metabolic hyperbola, describing how much VE must change to obtain a given change in PaCO₂ (the so-called “plant gain”) has two characteristics which are relevant to weaning. First, it is lower at higher VE [38] (see Fig. 2 panel A). Therefore, during weaning, higher changes in VE are required to achieve a new PaCO₂ set-point if the patient is already hyperventilating prior to the trial. This might be one reason why high breathing effort before or during a weaning trial has been associated with weaning failure [19, 20]. Second the slope decreases when the V'CO_{2ML} is decreased [37]. Accordingly reaching a new PaCO₂ set-point (e.g. because of hypoxaemia) requires much more effort during the later stages of a weaning trial. For both reasons, avoiding hypoxaemia, distress or any other cause for a shift in the eupneic threshold is important during a weaning trial.

Monitoring respiratory centres output

Respiratory centres can express their output in terms of timing or intensity: the timing is reflected by respiratory rate, while the intensity of output is referred to as respiratory drive. Respiratory rate significantly increases only when respiratory drive is 3–4 times elevated [35, 36]. Similarly, clinical signs of high effort occur when drive is already excessive. For this reason, invasive assessment of drive is necessary to predict the success or failure of weaning prior to the development of overt distress. Directly measuring the rate of change of the electrical activity of the brain centres is not feasible in routine practice, thereby surrogates need to be employed. These surrogates relate more or less directly to respiratory drive (the electrical activity of the diaphragm, EAdi [45]), others with respiratory effort (P0.1 [46], the swing in oesophageal, ΔP_{eso} , and transdiaphragmatic pressure, ΔP_{di} [47], or the muscle pressure, P_{muscle} , and the occlusion pressure, P_{occ} [48]), others with lung stress (dynamic transpulmonary pressure, ΔPL [47, 48]). If the descending pathway is altered (neuromuscular impairment, increased respiratory system elastance), as typically seen in patient undergoing V–V ECMO, a dissociation between these indices might occur, thereby complicating the assessment of the respiratory centres output.

The ventilator

We have discussed the effects of weaning extracorporeal parameters on V'O_{2ML} and V'CO_{2ML} together with the resulting interactions with the patient's respiratory centres.

In the following section, we will discuss the approach to mechanical ventilation during a weaning trial.

Passive controlled patients

In fully sedated patients in controlled modes, changes in extracorporeal gas exchange may be directly reflected in the systemic arterial blood gases if concomitant changes in mechanical ventilation are not made. For safe decannulation from V–V ECMO, maintenance of gas exchange must not be at the cost of excessive risk of ventilator induced lung injury (VILI). Overall, protective ventilation during V–V ECMO is debated [49]. The holistic concept of mechanical power [50] particularly highlights the harms of respiratory rate as well as driving pressure [51], though safety thresholds are unclear [52, 53]. Associations between mortality and the use of higher driving pressure [54], and mechanical power [55] during V–V ECMO have been made from cohort studies and a period of total lung rest with zero driving pressure was correlated with lower plasma biomarkers of lung injury in a recent small randomized trial [56]. However, ultra-protective ventilation may be unnecessarily cautious when patients have improved to the point of a weaning trial off. Finally, increased sedation or even neuromuscular blockade may be required to maintain synchrony if ventilation is not adequately adjusted to match the demands of the brain curve.

Spontaneously breathing patients

The spontaneously breathing patient's respiratory centre's output will dynamically increment to maintain gas exchange as extracorporeal support is weaned. Changes in respiratory centres output during weaning translate into breathing effort and lung stress which is the main contributor to patient self-induced lung injury (P-SILI) [57]. The role of the ventilator in reducing breathing effort and stress is crucial and can be divided into two components:

Manoeuvres reducing effort and stress

Any manoeuvre shifting the CO₂ sensitivity curve to higher PaCO₂ or improving the matching between the ventilation and the brain curve may reduce breathing effort and lung stress [35, 36]. The use of sedation, shifting the CO₂ sensitivity curve to the right, is a typical 'non-ventilatory' strategy in this regard. Increasing FiO₂ and PEEP (if associated with recruitment) may have beneficial effects. However, increasing PEEP may worsen neuromechanical uncoupling [42] and it can increase the *static* stress to the lung contributing to the total mechanical power of ventilation [50, 58]. Manoeuvres improving patient–ventilator synchrony also have the potential to reduce effort and regional stress [57].

Manoeuvres reducing effort but not stress

Any manoeuvre unloading the respiratory muscles (e.g. increasing pressure support) has the potential to reduce breathing effort, but not lung stress. Indeed, when the respiratory centres are set to maintain a certain PaCO₂, pressure support leads to a decreased workload to the respiratory muscles, but the total ventilation required to maintain PaCO₂ does not change (i.e. stress will not decrease) [59].

Table 4 Stopping criteria during weaning from V–V ECMO

Parameter	Values of concern	Downsides
Oxygen saturation	< 88%	Late sign of distress
Heart rate	> 110	Multifactorial causes
PaCO ₂	New respiratory acidosis	Late sign of distress
Respiratory rate	> 35	Late sign of distress
Tidal volume	> 8 ml/kg IBW	Depends on respiratory system elastance
Driving pressure	> 15 cm H ₂ O	Evaluates both lung and chest wall
P 0.1	> 10 cmH ₂ O	May be falsely low in patients with respiratory muscle weakness
ΔP _{eso}	< – 15 cmH ₂ O	Requires an oesophageal catheter
P _{occ}	< – 20 cmH ₂ O	Requires multiple manual manoeuvres
P _{musc} *	> 10 cmH ₂ O	Requires measurement (or estimation) of chest wall elastance
ΔP _L	> 20 cmH ₂ O	Requires oesophageal catheter
Total lung stress (PEEP _L + ΔP _L)	Unknown	Difficult assessment of PEEP _L in patients with abdominal contraction

PEEP_L: static stress associated with PEEP

*P_{musc} can be derived from the oesophageal pressure swing and the estimated chest wall elastance. Alternatively, it can be estimated from $-0.75 \times P_{occ}$

Irrespective of the manoeuvre performed, general principles of lung protection during a weaning trial in spontaneously breathing patients are similar to those in fully sedated patients under controlled ventilation (Table 4 [14, 19, 20, 57] summarizes possible stopping criteria of a weaning trial from V–V ECMO). However, some important specifics must be highlighted:

1. The presence of active muscular contraction, variable between inspiration and expiration, confounds the estimation of chest wall compliance. One implication is that whole respiratory system indices like driving pressure might less reliably reflect lung stress than during passive ventilation. Additionally, abdominal muscle contraction may both reduce the static stress associated with PEEP [60, 61] and alter the estimation of effort with oesophageal pressure if gastric pressure is not concomitantly measured [47].
2. Indices of effort represent an “average” measurement of the stress applied to the lung. Indeed, in spontaneous breathing, significant regional changes in oesophageal and transpulmonary pressure can occur [62]. This may elicit pendelluft and negative pressure alveolar oedema, worsening P-SILI [57]. Although PEEP can increase lung homogeneity counteracting these effects [63, 64], its downsides must be kept in mind.

Importantly, if the patient is spontaneously breathing, the development of hypercapnia or respiratory distress are late signs (panel B Fig. 3). Accordingly, measurement of drive and effort is essential to optimize mechanical ventilation and avoid exposing the patient to P-SILI and premature decannulation. Even with ‘protective’ parameters measured from the airway, the spontaneous effort to maintain normocapnia can generate enormous transpulmonary pressures [65]. Increased tidal volumes (driven by increased dead




Fig. 3 Our process of weaning V-V ECMO. **A** Sequence for V-V ECMO weaning. Throughout, monitor for stopping criteria. **B** As SGF is weaned, the proportion of metabolically produced CO₂ cleared by the natural lung (V'CO_{2NL}/V'CO_{2tot}) increases. In patients who are not yet suitable for decannulation, this load can only be managed with excessive effort (see next panels). Ventilatory efficiency can be expressed as the ratio of the effort (or minute ventilation) to the V'CO_{2NL}. In patients who fail a weaning trial ventilatory efficiency is usually worse, and may deteriorate as the demands on the respiratory system rise. If they are not able to clear all of the metabolically produced CO₂ then hypercapnia ensues. **C** Monitoring drive and effort during a weaning trial. Waveforms during a pressure supported breath, an expiratory occlusion throughout an inspiratory cycle and an end inspiratory occlusion. **D** Targets to maintain during a trial off V-V ECMO including measures of drive (P0.1), effort (Poccc or ΔP_{es} if available), stress (ΔP_L or DP if not available) and native lung ventilator efficiency (ΔP_{es}/V'CO_{2NL}, end tidal CO₂ to arterial CO₂ ratio (ETCO₂:PaCO₂) or the ratio of minute ventilation to clearance (VE/V'CO_{2NL}). At our centre, volumetric capnography from the ventilator and pre- and post- oxygenator blood gases are used to calculate the V'CO_{2NL} and V'CO_{2ML}, respectively. Unfortunately, during weaning the V'CO_{2NL} is not routinely measured. However, this is done in individual patients who have a pulmonary artery catheter for measurement of C_vmixed O₂ or a receive calorimetric measurements. FdO₂: the fraction of oxygen of the sweep gas flow (SGF), TV: tidal volume, P0.1: pressure deflection during 100 ms of occlusion, Poccc: maximal pressure deflection during occlusion, ΔP_{es}: oesophageal pressure swing, ΔP_{aw}: plateau after inspiratory inclusion, including the PMI: rebound pressure from relaxing inspiratory muscles, ΔP_L: transpulmonary pressure

space) and new tachycardia predicted unsafe decannulation in a recent case series, but ΔP_{es} of > 16 cmH₂O had the greatest accuracy [20].

A proposed approach to weaning

Our approach to weaning is represented in Fig. 3 [14]. Prior to commencing weaning comprehensive assessment of respiratory drive, effort, mechanical ventilation and the CO₂ clearance capacity of the lung should take place, both to optimize mechanical assistance and as a baseline measure. The V'CO_{2NL} should be at least 50% of the total metabolically produced carbon dioxide. Our preference is for patients to be on a spontaneous or assisted mode of ventilation. First the FiO₂ is set to 0.6 in anticipation of reducing V'O_{2ML} and to avoid alveolar hypoxia as the respiratory quotient is changed during

weaning. The ECBF is held static unless there is suspicion of an intracardiac shunt. Next, the FdO_2 is sequentially weaned in 5-min intervals, allowing for re-establishment of hypoxic pulmonary vasoconstriction and potentially increasing native ventilatory efficiency with improved V/Q matching. If an FdO_2 of 0.21 is tolerated, next the SGF is sequentially decreased to zero in 5–10 min intervals. As the $V'CO_{2ML}$ falls, monitoring continues to ensure increasing $V'CO_{2NL}$ is not at the cost of injurious effort or stress. In all patients, the total $V'CO_2$ will rise due to the increasing work of breathing to manage the load from the $V'CO_{2ML}$. Depending on the pulmonary mechanics and ventilatory efficiency, in some patients the native lungs will not be capable of managing this load and they will demonstrate increasing respiratory drive, effort, minute ventilation, sympathetic activation and ultimately hypercapnia. Time to equilibrate at each step is essential in order to fully assess response and prevent P-SILL. Throughout, multimodal monitoring is continued, and the weaning test is ceased if there are indices of concern (see Table 3 and Fig. 3). As decannulation itself often produces a systemic inflammatory response in the following days, our preference is for a conservative approach to decannulation and a trial off SGF of 24 h.

Conclusions

The rationale for the use of V–V ECMO in ARDS and other forms of severe respiratory failure is becoming clearer. However, variation in mortality between centres [8] and a lack of prospective randomized evidence regarding the management of patients on V–V ECMO means there is a strong scientific rationale for further study. Early, safe liberation from V–V ECMO has the potential to hasten patient's recovery and maintain equity of access to other patients who may benefit from this effective, but resource-intensive treatment. Although there is not yet high-grade evidence to guide clinicians, we have outlined an approach to weaning underpinned by physiology. The feasibility of weaning from V–V ECMO should be considered daily. We advocate separating the ability of the natural lung to provide O_2 and remove CO_2 by weaning the FdO_2 prior to the SGF. The complex interactions between the determinants of respiratory drive, the patient's effort and ventilatory assistance, their lung mechanics and efficiency of $V'CO_{2NL}$ will determine the outcome of a weaning trial. Care must be taken to avoid occult P-SILI in patients making spontaneous effort and we advocate multimodal assessment of drive, effort and stress throughout the weaning process.

Acknowledgements

All figures created using Biorender. Figure 1 adapted from a template created by Dr. Yevgeniy Brailovsky from Sidney Kimmel School of Medicine.

Author contributions

All authors contributed to the text. PC formulated the figures with input from co-authors. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

Not applicable to this narrative review.

Declarations

Ethics approval and consent to participate

This narrative review did not require ethical approval.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 21 October 2022 Accepted: 18 January 2023

Published online: 10 February 2023

References

1. Barbaro RP, Odetola FO, Kidwell KM, Paden ML, Bartlett RH et al (2015) Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. *Am J Respir Crit Care Med* 191:894–901. <https://doi.org/10.1164/rccm.201409-1634OC>
2. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM et al (2009) Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *Lancet* 374:1351–1363. [https://doi.org/10.1016/S0140-6736\(09\)61069-2](https://doi.org/10.1016/S0140-6736(09)61069-2)
3. Combes A, Hajage D, Capellier G, Demoule A, Lavoue S, Guervilly C et al (2018) Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. *N Engl J Med* 378:1965–1975. <https://doi.org/10.1056/NEJMoa1800385>
4. Combes A, Peek GJ, Hajage D, Hardy P, Abrams P, Schmidt M et al (2020) ECMO for severe ARDS: systematic review and individual patient data meta-analysis. *Intensive Care Med* 46:2048–2057. <https://doi.org/10.1007/s00134-020-06248-3>
5. Warren A, Chiu YD, Villar SS, Fowles JA, Symes N, Barker J et al (2020) Outcomes of the NHS England National Extracorporeal Membrane Oxygenation Service for adults with respiratory failure: a multicentre observational cohort study. *Br J Anaesth* 125:259–266
6. Tonna JE, Abrams D, Brodie D, Greenwood JC, Mateo-Sidron JAR, Usman A et al (2021) Management of adult patients supported with venovenous extracorporeal membrane oxygenation (VV ECMO): guideline from the extracorporeal life support organization (ELSO). *ASAIO J* 67:601–610. <https://doi.org/10.1097/MAT.00000000000001432>
7. Gannon WD, Stokes JW, Francois SA, Patel YJ, Pugh ME, Benson C et al (2022) Association between availability of extracorporeal membrane oxygenation and mortality in patients with COVID-19 eligible for extracorporeal membrane oxygenation: a natural experiment. *Am J Respir Crit Care Med* 205:1354–1357. <https://doi.org/10.1164/rccm.202110-2399LE>
8. Sen A, Callisen HE, Alwardt CM et al (2016) Adult venovenous extracorporeal membrane oxygenation for severe respiratory failure: current status and future perspectives. *Ann Card Anaesth* 19:97–111. <https://doi.org/10.4103/0971-9784.173027>
9. Reeb J, Olland A, Pottecher J et al (2017) Extracorporeal membrane oxygenation for acute respiratory distress syndrome after pneumonectomy. *Ann Thorac Surg* 103:881–889. <https://doi.org/10.1016/j.athoracsur.2016.11.038>
10. Broman LM, Walfertheiner MV, Montisci A, Pappalardo F (2018) Weaning from veno-venous extracorporeal membrane oxygenation: how I do it. *J Thorac Dis* 10:S692–S697. <https://doi.org/10.21037/jtd.2017.09.95>
11. Grant AA, Hart VJ, Lineen EB, Badiye A, Byers PM, Patel A et al (2018) A weaning protocol for venovenous extracorporeal membrane oxygenation with a review of the literature. *Artif Organs* 42:605–610. <https://doi.org/10.1111/aor.13087>
12. Seiler F, Trudzinski FC, Horsch SI et al (2018) Weaning from prolonged veno-venous extracorporeal membrane oxygenation (ECMO) after transfer to a specialized center: a retrospective study. *J Artif Organs* 21:300–307. <https://doi.org/10.1007/s10047-018-1046-1>
13. Chaves RCF, Rabello Filho R, Timenetsky KT et al (2019) Extracorporeal membrane oxygenation: a literature review. *Rev Bras Ter Intensiva* 31:410–424. <https://doi.org/10.5935/0103-507X.20190063>
14. Vasques F, Romitti F, Gattinoni L, Camporata L (2019) How I wean patients from veno-venous extra-corporeal membrane oxygenation. *Crit Care* 23:316. <https://doi.org/10.1186/s13054-019-2592-5>
15. Li X, Guo Z, Li B et al (2020) Extracorporeal membrane oxygenation for coronavirus disease 2019 in Shanghai, China. *ASAIO J* 66:475–481. <https://doi.org/10.1097/MAT.0000000000001172>
16. Gannon WD, Stokes JW, Bloom S, Sherrill W, Bacchetta M, Rice TW et al (2021) Safety and feasibility of a protocolized daily assessment of readiness for liberation from venovenous extracorporeal membrane oxygenation. *Chest* 160:1693–1703. <https://doi.org/10.1016/j.chest.2021.05.066>
17. Teijeiro-Paradis R, Tiwari P, Spriel A, Del Sorbo L, Fan E (2021) Standardized liberation trials in patients with COVID-19 ARDS treated with venovenous extracorporeal membrane oxygenation: when ready, let them breathe! *Intensive Care Med* 47:1494–1496. <https://doi.org/10.1007/s00134-021-06523-x>
18. Belliato M, Cremascoli L, Epis F et al (2021) Carbon dioxide elimination during veno-venous extracorporeal membrane oxygenation weaning: a pilot study. *ASAIO J* 67:700–708. <https://doi.org/10.1097/MAT.0000000000001282>
19. Al-Fares AA, Ferguson ND, Ma J, Cypel M, Keshavjee S, Fan E et al (2021) Achieving safe liberation during weaning from V-V ECMO in patients with severe ARDS: the role of tidal volume and inspiratory effort. *Chest* 160:1704–1713. <https://doi.org/10.1016/j.chest.2021.05.068>
20. Lazzari S, Romitti F, Busana M, Vassalli F, Bonifazi M, Macri MM et al (2022) End-tidal to arterial PACO₂ ratio as guide to weaning from veno-venous extra-corporeal membrane oxygenation. *Am J Respir Crit Care Med*. <https://doi.org/10.1164/rccm.202201-0135OC>

21. Ficial B, Vasques F, Zhang J, Whebell S, Slattery M, Lamas T et al (2021) Physiological basis of extracorporeal membrane oxygenation and extracorporeal carbon dioxide removal in respiratory failure. *Membranes (Basel)* 11:225. <https://doi.org/10.3390/membranes11030225>
22. Karagiannidis C, Strassmann S, Brodie D, Ritter P, Larsson A, Borchardt R, Windisch W (2017) Impact of membrane lung surface area and blood flow on extracorporeal CO₂ removal during severe respiratory acidosis. *Intensive Care Med Exp* 5:34. <https://doi.org/10.1186/s40635-017-0147-0>
23. Duscio E, Cipulli F, Vasques F, Collino F, Rapetti F, Romitti F, Behnemann T, Niewenhuys J, Tonetti T, Pasticci I, Vassalli F, Reupke V, Moerer O, Quintel M, Gattinoni L (2019) Extracorporeal CO₂ removal: the minimally invasive approach, theory, and practice. *Crit Care Med* 47:33–40. <https://doi.org/10.1097/CCM.0000000000003430>
24. Marshall BE, Marshall C (1985) A model for hypoxic constriction of the pulmonary circulation. *J Appl Physiol* 1988(64):68–77. <https://doi.org/10.1152/jappl.1988.64.1.68>
25. Bishop MJ, Cheney FW (1983) Effects of pulmonary blood flow and mixed venous O₂ tension on gas exchange in dogs. *Anesthesiology* 58:130–135. <https://doi.org/10.1097/0000542-198302000-00005>
26. Domino KB, Wetstein L, Glasser SA, Lindgren L, Marshall C, Harken A, Marshall BE (1983) Influence of mixed venous oxygen tension (PVO₂) on blood flow to atelectatic lung. *Anesthesiology* 59:428–434. <https://doi.org/10.1097/0000542-198311000-00012>
27. Tarry D, Powell M (2017) Hypoxic pulmonary vasoconstriction. *BJA Educ* 17:208–213. <https://doi.org/10.1093/bjaed/mkw076>
28. Sinha P, Calfee CS, Beitler JR, Soni N, Ho K, Matthay MA et al (2019) Physiologic analysis and clinical performance of the ventilatory ratio in acute respiratory distress syndrome. *Am J Respir Crit Care Med* 199:333–341. <https://doi.org/10.1164/rccm.201804-0692OC>
29. Suarez-Sipmann F, Villar J, Fernando C, Sanchez-Giralt JA, Tusman G (2021) Monitoring expired CO₂ kinetics to individualize lung-protective ventilation in patients with the acute respiratory distress syndrome. *Front Physiol* 12:785014. <https://doi.org/10.3389/fphys.2021.785014>
30. Bonifazi M, Romitti F, Busana M, Palumbo MM, Steinberg I, Gattarello S et al (2021) End-tidal to arterial PCO₂ ratio: a bedside meter of the overall gas exchanger performance. *Intensive Care Med Exp* 9:21. <https://doi.org/10.1186/s40635-021-00377-9>
31. Gillon SA, Barrett NA, Ioannou N, Camporota L, Victor K, Gowland A et al (2016) Intracardiac right-to-left shunt impeding liberation from veno-venous extracorporeal membrane oxygenation: two case studies. *Crit Care Med* 44:e583–e586. <https://doi.org/10.1097/CCM.0000000000001619>
32. Gattinoni L, Coppola S, Camporota L (2022) Physiology of extracorporeal CO₂ removal. *Intensive Care Med* 48:1322–1325. <https://doi.org/10.1007/s00134-022-06827-6>
33. Cipriani E, Langer T, Bottino N, Brusatori S, Carlesso E, Colombo SM et al (2020) Key role of respiratory quotient to reduce the occurrence of hypoxemia during extracorporeal gas exchange: a theoretical analysis. *Crit Care Med* 12:e1327–e1331. <https://doi.org/10.1097/CCM.0000000000004619>
34. Dickstein ML (2020) Extracorporeal CO₂ removal and the alveolar gas equation. *Am J Respir Crit Care Med* 1(202):1057–1058. <https://doi.org/10.1164/rccm.202005-1609LE>
35. Vaporidi K, Akoumianaki E, Telias I, Goligher EC, Brochard L, Georgopoulos D (2020) Respiratory drive in critically ill patients. Pathophysiology and clinical implications. *Am J Respir Crit Care Med* 201:20–32. <https://doi.org/10.1164/rccm.201903-0596SO>
36. Spinelli E, Mauri T, Beitler JR, Pesenti A, Brodie D (2020) Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions. *Intensive Care Med* 46:606–618. <https://doi.org/10.1007/s00134-020-05942-6>
37. Asmussen E, Nielsen M (1957) Ventilatory response to CO₂ during work at normal and at low oxygen tensions. *Acta Physiol Scand* 39:27–35. <https://doi.org/10.1111/j.1748-1716.1957.tb01406.x>
38. Haouzi P (2022) Revisiting the effects of the reciprocal function between alveolar ventilation and CO₂ partial pressure (PACO₂) on PACO₂ homeostasis at rest and in exercise. *J Appl Physiol* (1985). <https://doi.org/10.1152/japplphysiol.00058.2022>
39. Spinelli E, Mauri T, Lissoni A, Crotti S, Langer T, Albanese N et al (2020) Spontaneous breathing patterns during maximum extracorporeal CO₂ removal in subjects with early severe ARDS. *Respir Care* 65:911–919. <https://doi.org/10.4187/respcare.07391>
40. Yoshida T, Fujino Y, Amato MBP, Kavanagh BP (2017) Fifty Years of Research in ARDS. Spontaneous breathing during mechanical ventilation. Risks, mechanisms, and management. *Am J Respir Crit Care Med* 195:985–992. <https://doi.org/10.1164/rccm.201604-0748CP>
41. Briscoe WA, Dubois AB (1958) The relationship between airway resistance, airway conductance and lung volume in subjects of different age and body size. *J Clin Invest* 37:1279–1285. <https://doi.org/10.1172/JCI103715>
42. Jansen D, Jonkman AH, de Vries HJ, Wennen M, Elshof J, Hoofs MA et al (2021) Positive end-expiratory pressure affects geometry and function of the human diaphragm. *J Appl Physiol* (1985) 131(4):1328–1339. <https://doi.org/10.1152/japplphysiol.00184.2021>
43. Forster HV, Haouzi P, Dempsey JA (2012) Control of breathing during exercise. *Compr Physiol* 2:743–777. <https://doi.org/10.1002/cphy.c100045>
44. Giosa L, Busana M, Bonifazi M, Romitti F, Vassalli F, Pasticci I et al (2021) Mobilizing carbon dioxide stores. An experimental study. *Am J Respir Crit Care Med* 203:318–327. <https://doi.org/10.1164/rccm.202005-1687OC>
45. Dres M, Demoule A (2020) Monitoring diaphragm function in the ICU. *Curr Opin Crit Care* 26(1):18–25. <https://doi.org/10.1097/MCC.0000000000000682>
46. Sato R, Hasegawa D, Hamahata NT, Narala S, Nishida K et al (2021) The predictive value of airway occlusion pressure at 100 msec (P0.1) on successful weaning from mechanical ventilation: a systematic review and meta-analysis. *J Crit Care* 63:124–132. <https://doi.org/10.1016/j.jcrrc.2020.09.030>
47. Kassis EB, Talmor D (2021) Clinical application of esophageal manometry: how I do it. *Crit Care* 25:6. <https://doi.org/10.1186/s13054-020-03453-w>

48. Bertoni M, Telias I, Urner M, Long M, Del Sorbo L, Fan E et al (2019) A novel non-invasive method to detect excessively high respiratory effort and dynamic transpulmonary driving pressure during mechanical ventilation. *Crit Care* 23:346. <https://doi.org/10.1186/s13054-019-2617-0>
49. Abrams D, Schmidt M, Pham T, Beitler JR, Fan E, Goligher EC et al (2020) Mechanical ventilation for acute respiratory distress syndrome during extracorporeal life support: research and practice. *Am J Respir Crit Care Med* 201:514–525
50. Gattinoni L, Tonetti T, Cressoni M, Cadringer P, Herrmann P, Moerer O et al (2016) Ventilator-related causes of lung injury: the mechanical power. *Intensive Care Med* 42:1567–1575. <https://doi.org/10.1007/s00134-016-4505-2>
51. Amato MBP, Meade MO, Slutsky AS, Brochard L, Costa ELV, Schoenfeld DA et al (2015) Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med* 372:747–755. <https://doi.org/10.1056/NEJMsa1410639>
52. Serpa Neto A, Deliberato RO, Johnson AEW, Bos LD, Amorim P, Pereira SM et al (2018) Mechanical power of ventilation is associated with mortality in critically ill patients: an analysis of patients in two observational cohorts. *Intensive Care Med* 44:1914–1922
53. Romitti F, Busana M, Palumbo MM, Bonifazi M, Giosa L, Vassalli F et al (2022) Mechanical power thresholds during mechanical ventilation: an experimental study. *Physiol Rep* 10:e15225. <https://doi.org/10.14814/phy2.15225>
54. Neto AS, Schmidt M, Azevedo LCP, Bein T, Brochard L, Beutel G et al (2016) Associations between ventilator settings during extracorporeal membrane oxygenation for refractory hypoxemia and outcome in patients with acute respiratory distress syndrome: a pooled individual patient data analysis: mechanical ventilation during ECMO. *Intensive Care Med* 42:1672–1684. <https://doi.org/10.1007/s00134-016-4507-0>
55. Chiu LC, Lin SW, Chuang LP, Li HH, Liu PH, Tsai FC et al (2021) Mechanical power during extracorporeal membrane oxygenation and hospital mortality in patients with acute respiratory distress syndrome. *Crit Care* 25:13. <https://doi.org/10.1186/s13054-020-03428-x>
56. Del Sorbo L, Goffi A, Tomlinson G, Pettenuzzo T, Facchin F, Vendramin A et al (2020) Effect of driving pressure change during extracorporeal membrane oxygenation in adults with acute respiratory distress syndrome: a randomized crossover physiologic study. *Crit Care Med* 48:1771–1778. <https://doi.org/10.1097/CCM.0000000000004637>
57. Goligher EC, Jonkman AH, Dianti J, Vaporidi K, Beitler JR, Bhakti K et al (2020) Clinical strategies for implementing lung and diaphragm-protective ventilation: avoiding insufficient and excessive effort. *Intensive Care Med* 46:2314–2326. <https://doi.org/10.1007/s00134-020-06288-9>
58. Vassalli F, Pasticci I, Romitti F, Duscio E, Aßmann J, Grünhagen H et al (2020) Does iso-mechanical power lead to iso-lung damage? An experimental study in a porcine model. *Anesthesiology* 132:1126–1137. <https://doi.org/10.1097/ALN.0000000000003189>
59. Bellani G, Grasselli G, Teggia-Droggi M, Mauri T, Coppadoro A, Brochard L et al (2016) Do spontaneous and mechanical breathing have similar effects on average transpulmonary and alveolar pressure? A clinical crossover study. *Crit Care* 20:142. <https://doi.org/10.1186/s13054-016-1290-9>
60. Shi ZH, Jonkman A, de Vries H, Jansen D, Ottenheim C, Girbes A et al (2019) Expiratory muscle dysfunction in critically ill patients: towards improved understanding. *Intensive Care Med* 45:1061–1071. <https://doi.org/10.1007/s00134-019-05664-4>
61. Chandra A, Coggshall JW, Ravenscraft SA, Marini JJ (1994) Hyperpnea limits the volume recruited by positive end-expiratory pressure. *Am J Respir Crit Care Med* 150:911–917. <https://doi.org/10.1164/ajrccm.150.4.7921462>
62. Yoshida T, Amato MBP, Grieco DL, Chen L, Lima CAS, Roldan R et al (2018) Esophageal manometry and regional transpulmonary pressure in lung injury. *Am J Respir Crit Care Med* 197:1018–1026. <https://doi.org/10.1164/rccm.201709-1806OC>
63. Sang L, Zhao Z, Yun PJ, Frerichs I, Möller K, Fu F et al (2020) Qualitative and quantitative assessment of pendelluft: a simple method based on electrical impedance tomography. *Ann Transl Med* 8:1216. <https://doi.org/10.21037/atm-20-4182>
64. Morais CCA, Koyama Y, Yoshida T, Plens GM, Gomes S, Lima et al (2018) High positive end-expiratory pressure renders spontaneous effort noninjurious. *Am J Respir Crit Care Med* 197:1285–1296. <https://doi.org/10.1164/rccm.201706-1244OC>
65. Mauri T, Langer T, Zanella A, Grasselli G, Pesenti A (2016) Extremely high transpulmonary pressure in a spontaneously breathing patient with early severe ARDS on ECMO. *Intensive Care Med* 42:2101–2103. <https://doi.org/10.1007/s00134-016-4470-9>

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.